A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

NCT06946927 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: JMKX001899
DRUG: IN10018
DRUG: Chemotherapy: Pemetrexed
DRUG: Carboplatin

Sponsor

Jemincare